Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank C Barone

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Experimental Neurology|May 9, 2008
SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protectionJeffrey J Legos, Stephen C Lenhard, Robin E Haimbach, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 22, 2002
The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertensionChristian T Abrahamsen, Frank C Barone, Wallace G Campbell, et al.
The Journal of Thoracic and Cardiovascular Surgery|December 3, 2014
Feasibility of near-infrared spectroscopic tomography for intraoperative functional cerebral monitoring: a primate studyDaniel C Lee, Tigran Gevorgyan, Harry L Graber, et al.
Geroscience|June 21, 2025
The future of biomarkers for vascular contributions to cognitive impairment and dementia (VCID): proceedings of the 2025 annual workshop of the Albert research institute for white matter and cognitionMatthew J Lennon, Nikolaos Karvelas, Aravind Ganesh, et al.
Brain Communications|November 20, 2020
Cerebrovascular disease promotes tau pathology in Alzheimer's diseaseKrystal K Laing, Sabrina Simoes, Gloria P Baena-Caldas, et al.
Journal of Translational Medicine|February 14, 2016
First translational 'Think Tank' on cerebrovascular disease, cognitive impairment and dementiaFrank C Barone, Deborah Gustafson, Howard A Crystal, et al.
Geroscience|July 21, 2025
Advancing clinical trial readiness in white matter disease and related dementias: key steps for future research progressPradoldej Sompol, Gregory A Jicha, Jason D Hinman, et al.
Geroscience|October 4, 2021
Expanding the horizon of research into the pathogenesis of the white matter diseases: Proceedings of the 2021 Annual Workshop of the Albert Research Institute for White Matter and CognitionShawn N Whitehead, Askiel Bruno, Jeffrey M Burns, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 26, 2001
Nonpeptide tachykinin receptor antagonists. III. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper-reactivity in guinea pigsDouglas W P Hay, Giuseppe A M Giardina, Don E Griswold, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Experimental Neurology|May 9, 2008
SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protectionJeffrey J Legos, Stephen C Lenhard, Robin E Haimbach, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 22, 2002
The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertensionChristian T Abrahamsen, Frank C Barone, Wallace G Campbell, et al.
The Journal of Thoracic and Cardiovascular Surgery|December 3, 2014
Feasibility of near-infrared spectroscopic tomography for intraoperative functional cerebral monitoring: a primate studyDaniel C Lee, Tigran Gevorgyan, Harry L Graber, et al.
Geroscience|June 21, 2025
The future of biomarkers for vascular contributions to cognitive impairment and dementia (VCID): proceedings of the 2025 annual workshop of the Albert research institute for white matter and cognitionMatthew J Lennon, Nikolaos Karvelas, Aravind Ganesh, et al.
Brain Communications|November 20, 2020
Cerebrovascular disease promotes tau pathology in Alzheimer's diseaseKrystal K Laing, Sabrina Simoes, Gloria P Baena-Caldas, et al.
Journal of Translational Medicine|February 14, 2016
First translational 'Think Tank' on cerebrovascular disease, cognitive impairment and dementiaFrank C Barone, Deborah Gustafson, Howard A Crystal, et al.
Geroscience|July 21, 2025
Advancing clinical trial readiness in white matter disease and related dementias: key steps for future research progressPradoldej Sompol, Gregory A Jicha, Jason D Hinman, et al.
Geroscience|October 4, 2021
Expanding the horizon of research into the pathogenesis of the white matter diseases: Proceedings of the 2021 Annual Workshop of the Albert Research Institute for White Matter and CognitionShawn N Whitehead, Askiel Bruno, Jeffrey M Burns, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 26, 2001
Nonpeptide tachykinin receptor antagonists. III. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper-reactivity in guinea pigsDouglas W P Hay, Giuseppe A M Giardina, Don E Griswold, et al.
Pageof 5